Get the Daily Brief
Latest Biotech News
AI-Guided Cardiovascular Disease Prevention: Launch of Corsera Health
Biotech veterans John Maraganore and Clive Meanwell have launched Corsera Health, aiming to prevent cardiovascular disease through an AI-powered early risk assessment tool combined with a...
Novartis Bets Big on RNAi Therapy for Parkinson’s Disease
Novartis has entered a high-stakes collaboration with Arrowhead Pharmaceuticals, licensing their preclinical RNA interference therapy ARO-SNCA targeting alpha-synuclein, a key protein involved in...
Ionis Triumphant with Olezarsen, Eyes Expanding Triglyceride Market
Ionis Pharmaceuticals reported positive pivotal Phase 3 results for olezarsen, significantly lowering triglyceride levels by up to 72% in patients with severe hypertriglyceridemia (sHTG) and...
Eli Lilly’s Oral GLP-1 Orforglipron Shows Strong Obesity Trial Results
Eli Lilly disclosed robust Phase 3 outcomes from its oral GLP-1 receptor agonist, orforglipron, achieving significant weight loss and glycemic improvements in obese and overweight adults with type...
Amgen’s $600 Million California R&D Center and Royalty Deal Highlight Growth
Amgen announced a $600 million investment to build a new state-of-the-art research and development facility in Thousand Oaks, California, slated to accelerate next-generation drug discovery and...
Advance in CAR T-Cell Therapy Development and Boosting Efficacy
The evolving CAR T-cell therapy field now benefits from streamlined end-to-end solutions offered by suppliers like Sino Biological, providing validated reagents and GMP-grade cytokines critical...
AI Models Set to Transform Cardiology and Medical Imaging
Artificial intelligence continues to make strides in healthcare, exemplified by a Graph Neural Network-based model developed at Mount Sinai for personalized anticoagulation decisions in atrial...
Breakthrough in Wearables and Biomedical Imaging Centers
Soochow University researchers reviewed advances in electrospun nanofiber composites for next-generation wearable electronic skin, with enhanced monitoring of physical and biofluid signals....
Regulatory and Market Movements: Biosimilars, FDA Updates, and Biosafety
The FDA reaffirmed overall survival as the gold standard endpoint in cancer trials while embracing alternative measures in certain contexts. European approval of Bio-Thera’s Stelara biosimilar...
Demographics and Mental Health: Aging, Autism, and Equity
Recent studies emphasize the nuanced experiences of aging and neurodivergence, including the challenges autistic individuals face during menopause, revealing gaps in tailored healthcare support....
Merck’s Oral PCSK9 Inhibitor Advances With Third Phase 3 Win
Merck & Co. has completed a third successful Phase 3 trial of its oral PCSK9 inhibitor in hyperlipidemia, pushing the drug closer to regulatory approval. The CORALreef program results solidify the...
Novartis Pays $200M Upfront to Arrowhead for RNAi Parkinson’s Therapy
Novartis has inked a $200 million upfront licensing deal with Arrowhead Pharmaceuticals for an RNA interference therapy targeting alpha-synuclein in Parkinson’s disease and related...
Ionis Olearsen Shows Landmark Phase 3 Efficacy in Severe Hypertriglyceridemia
Ionis Pharmaceuticals announced positive topline data from its pivotal Phase 3 CORE and CORE2 trials of olearsen in patients with severe hypertriglyceridemia (sHTG). The antisense oligonucleotide...
United Therapeutics’ Tyvaso Shows Phase 3 Breakthrough in IPF
United Therapeutics reported unexpected positive results from a Phase 3 trial of its inhaled treprostinil formulation, Tyvaso, in idiopathic pulmonary fibrosis (IPF). The study met its primary...
FDA Affirms Overall Survival as Gold Standard in Cancer Trials
The US Food and Drug Administration has reiterated that overall survival remains the preferred primary endpoint in oncology clinical trials. While acknowledging scenarios where surrogate endpoints...
Geneseeq Technology Wins FDA 510(k) Clearance for Tumor Profiling Assay
Geneseeq Technology has received FDA 510(k) clearance for its GeneseeqPrime next-generation sequencing (NGS) tumor profiling assay. This in vitro diagnostic test detects multiple classes of...
Medtronic and Abbott Win FDA OK for Diabetes Device Integration
Medtronic announced FDA clearance for integrating its MiniMed insulin pump with Abbott's Freestyle Libre continuous glucose monitoring system. This interoperability aims to streamline diabetes...
Charm Therapeutics Raises $80M to Advance AI-Designed Menin Inhibitor
Charm Therapeutics closed an $80 million Series B financing to fund clinical development of its next-generation menin inhibitor designed with artificial intelligence. The novel drug candidate aims...
Amgen Commits $600M to New California Research and Development Center
Amgen is investing $600 million to construct a new state-of-the-art research and development facility at its Thousand Oaks headquarters. This expansion will house hundreds of scientists focused on...
Shared Genomics Firms Golden Helix and Genomenon Partner to Integrate Clinical Informatics
Golden Helix announced a partnership with Genomenon to embed Genomenon’s Mastermind Genomic Intelligence platform and cancer knowledgebase into Golden Helix’s software suite for clinical labs...